NCT04866641View on ClinicalTrials.gov

Safety and Tolerability Study for T-1201 Injection 100 mg Kit in Patients With Advanced Solid Tumors

PHASE1RecruitingINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

June 24, 2021

Primary Completion Date

June 30, 2026

Study Completion Date

July 31, 2027

Conditions
Advanced Solid Tumor
Interventions
DRUG

T-1201 Injection 100 mg Kit

T-1201 Injection 100 mg Kit contains lyophilized powder with a sterile aqueous solution formulated for intravenous administration.

Trial Locations (2)

Unknown

RECRUITING

Kaohsiung Medical University Chung-Ho Memorial Hospital, Kaohsiung City

RECRUITING

National Cheng Kung University Hospital, Tainan City

All Listed Sponsors
lead

Taivex Therapeutics Corporation

INDUSTRY